Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CellProthera Selects CELLforCURE as Its CDMO Partner

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026. 

By: Rachel Klemovitch

Assistant Editor

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its CDMO partner for its planned Phase 3 trial for ProtheraCytes. CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches in 2026. 

ProtheraCytes is an autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack.

Last year, the company presented its Phase 3 design to the FDA and received favorable advice. Tech transfer and qualification of the bioproduction process in a specialized facility capable of releasing clinical batches of cellular products is an essential prerequisite for the start of Phase 3.

With promising results from a Phase 1/2b study of its lead ProtheraCytes, CellProthera has begun preparations for its late-stage clinical development.

“We selected CELLforCURE by SEQENS for the quality of its infrastructure, its equipment and the expertise of its team, who has already demonstrated its ability to release commercial batches of autologous therapies,” said Jean-Olivier Hirsch, Chief Operating Officer and Qualified Person of CellProthera. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics